HTB

IAS 10 Mexico City 2019

Dolutegravir for younger children: results from the ODYSSEY trial

Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

High efficacy from switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

Featured 10th IAS Conference on HIV Science (IAS 2019) in Mexico City

Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals

WHO recommends dolutegravir-based ART regimens for all

First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10

Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results

Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy

Fostemsavir: 96-week follow-up in people with multi-drug resistance

Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96

Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study

Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year